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Abstract:  Background:  Prognosis  of  heart  failure  in  metabolic  syndrome  is  not  well 
established because it represents a heterogenous spectrum of myocardial disorders that each 
may progress at different rates.  The present study determines the prognosis of heart failure in 
metabolic syndrome of middle aged individuals in terms of mortality and morbidity. Material 
and  Methods:  100  patients  studied  (60  with  metabolic  syndrome,  40  without  metabolic 
syndrome)  with  moderate – severe symptoms of heart  failure associated  with an ejection 
fraction equal or less than 40% and QRS duration of 130 sec or more were randomly selected. 
These patients were treated with conventional therapy for heart failure and monitored for 24 
weeks. Primary end points were NYHA class, distance walked in 6 minutes, and secondary 
end points were LVEF, LVEDD, SPAP and QRS duration. Result: As compared with the 
patients without metabolic syndrome,  metabolic syndrome patients experienced decrease in 
the distance walked in 6 minutes (336.40 ± 16.0 Vs 285.35 ± 3.30),  functional NYHA class 
improvement (75% Vs 33.3%), LVEF (35.22 ± 1.7 Vs 31.63 ± 2.74), In addition, metabolic 
syndrome group, required more hospitalizations and intravenous medications (50% Vs 10%). 
Conclusion: Moderate to severe heart failure patients with metabolic syndrome result in less 
significant improvement in heart failure when compared to heart failure without metabolic 
syndrome patients. 
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Introduction 
According to NCEP ATP III definition of metabolic syndrome ≥ 3 of the following 
criteria fulfilled. 
 
•  Fasting plasma glucose > 6.1 m.mol/l (110 mg/dl) 
•  Blood pressure ≥ 130 / 85 mm Hg 
•  Triglycerides ≥ 1.7 m.mol/l (150 mg/dl) 
•  HDL < 1.04 m.mol/l (40 ml/dl) for men and < 50 mg/dl for women. 
•  BMI > 29.40 Kg/mm
2 or waist circumference > 102 cm (men), > 85 cm (female). 
 
A modified definition of metabolic syndrome incorporating new cut-off points for 
waist circumference is studied for Asian Indians in India and migrant Asian Indians 
in  Singapore.  The  South  East  Asian  definition  includes  two  new  parameters; 
modified  waist  circumference  cut-off  point  (>  90  cm  in  males  and  >  80  cm  in 
females), modified body mass index cut-off point (> 23 kg/m
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South Asians classified as ‘metabolically obese’ or more appropriately dysfunctional. 
i.e. they have multiple metabolic derangements but are ‘non-obese by conventional 
BMI standards. These ‘non-obese’ people usually have high body fat, abdominal 
adiposity. Prevalence of MS varies across the globe.  The highest record prevalence 
world wide is in Native Americans, with nearly 60% of women, ages 45-49 & 45% 
of men, ages 45-49  meeting NCEP  ATP III criteria. Prevalence of MS in Asian 
population is lower than US and European population.  The overall incidence of MS 
in India – according to Kasiliwal in 2005 is 28.5%, by Guptha 2004 is 25%, by Ram 
Chandra in 2003 is 41%. In India the overall incidence of metabolic syndrome is 
29% highest at age group 40-50 years i.e., 33.7% and at 50-60 years i.e., 20.6. 
 
Heart failure is initiated after an “index event” either damaging the heart muscle, 
with a resultant loss of functioning cardiac myocytes, or disrupting the ability of 
myocardium  to  generate  force,  thereby  preventing  the  heart  from  contracting 
normally.  The index event may be an abrupt onset, as in myocardial infarction; it 
may be a gradual or insidious onset.  Regardless of nature following inciting event, 
the feature that is common to each of these index events is they all, in some manner, 
decline pumping capacity of the heart. In 1998 DALY (Disability adjusted life years) 
loss in India by heart failure is 26,932 and a share of total burden is 10% of all 
cardiovascular morbidities. Patients with HF undergo frequent admissions at rate of 
25% over 6 months period after initial hospitalization. Insulin resistance– and its 
clinical  surrogates  metabolic  syndrome  –  may  have  direct  myocardial  effects  in 
addition to their atherogenic effects, as insulin resistance is associated with systolic 
& diastolic dysfunction, with LV remodeling. A study conducted by Ingelsson E, 
Sundstron insulin resistance predicted CHF incidence was independently associated 
with  other  established  risk  factors.  Framingham  study  initially  established  that 
clinical history of DM independently associated with risk of developing HF, two fold 
increased risk in men and five fold increased risk in women. In a study conducted by 
Ford ES, Giles, the presence of heart failure is consistent with both the NCEP ATP 
III and WHO definitions of metabolic syndrome. 
 
Metabolic  syndrome  has  numerous  plausible  direct  myocardial  effects,  related  to 
insulin resistance and hyperinsulinaemia. 
 
•  Insulin may function as a growth factor in the myocardium a notification 
supported by experimental observation of increased myocardial mass and 
decreased cardiac output [1].   
•  Hyperinsulinaemia activates sympathetic nervous system, which is a causal 
factor for heart failure [2].  
•  Insulin resistance has recently been shown to increase the trophic effect of 
angiotensin  II  on  cellular  hypertrophy  and  collagen  formation  in  patients 
with hypertension, which lead to myocardial hypertrophy and fibrosis, both 
key substrate for heart failure [3]. 
 
Presence of myocardial insulin resistance has been demonstrated in diabetic patients 
with or without coronary artery disease suggesting that even early stages of altered 
glycemic control may affect myocardial metabolism. 
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Framingham heart study highlighted that after age 40, the life time risk of developing 
heart failure in subjects with blood pressure at 160/100 is twice that in those with 
blood pressure 140/90 and amplified by CAD, DM, LVH. As systolic pressure and 
pulse pressure appear to have a greater impact on risk of subsequent heart failure 
than the  diastolic pressure,  it  has  been  suggested that  stiffening  of  central  aorta, 
enhanced pulsatile bed, and altered vascular ventricular coupling may also play an 
important role in heart failure [4]. LVH appears to be an important intermediate in 
evolving heart failure, while risk of LVH is increasing progressively in relation to 
LV mass [5]. Among patients with heart failure in the general population, antecedent 
evidence of LVH is present in approximately 20% by ECG and 60-70% by echo [6]. 
Concentric LVH is highly coupled to abnormalities of myocardial relaxation and 
systolic  and  diastolic  ventricular  stiffening,  progressive  hypertrophy  is  also 
associated with the development of subtle abnormalities of systolic function, which 
may also enhance the vulnerability to heart failure development [7]. 
 
Other implications in pathogenesis of Hypertension and Heart Failure: 
 
1)  By  enhancing  speed  of  return  to  reflected  arterial  wave,  diminished  vascular 
compliance might augment end systolic load, ventricular wall stress and slowing 
myocardial relaxation [8]. 
2)  Analysis  of  cardiac structure and function  have  emphasized  that  patient  with 
heart failure and preserved ejection fraction are distinguished from those with 
hypertension by more pronounced abnormalities of active myocardial relaxation 
and passive diastolic stiffness [9], LV mass and left atrial remodeling [10]. 
3)  Hypertension  related  vascular  changes,  particularly  at  the level  of  the  elastic 
conduit arteries may play a important supporting role. 
 
Neuroendocrine Activation: Renin-angiotensin system is activated in HF. Site of 
release of renin is the juxtaglomerular apparatus of kidney and multiple stimuli may 
contribute to release of renin , reduced renal perfusion pressure, and diuretic therapy. 
Atrial  natriuretic  factor  and  vasopressin  may  inhibit  the  release  of  renin.  Renin 
enzymatically cleaves angiotensinogen, a tetrapeptide produced in the liver, to form 
the inactive decapeptide angiotensin I. Angiotensin I is converted to angiotensin II by 
the  angiotensin-converting  enzyme.  Angiotensin  II  is  a  potent  vasoconstrictor;  it 
promotes sodium reabsorption by increasing aldosterone secretion and by a direct 
effect on the tubules stimulates water intake by acting on thirst center. Angiotensin II 
facilitates release of norepinephrine by acting on sympathetic nerve endings.  
 
Neuroendocrine activation appears early in HF, studies suggests- Renin angiotensin 
aldosterone elevation is associated with poor prognosis in absence of treatment with 
ACE  inhibitors.  Plasma  norepinephrine  has  predicted  prognosis  in  several 
multivariate analyses [11]. Elevated levels of C-terminal and N-terminal atrial and 
brain natriuretic peptides suggests poor outcome in HF.  Elevated natriuretic peptide 
levels are associated with a poor long term prognosis after myocardial infarction 
[12]. Plasma endothelin is independent prognostic marker in HF [13]. Endothelin is a 
potent vasoconstrictor and causes pulmonary hypertension.  
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Hypertension and Pluricausal Cardiomyopathy: HTN is a risk factor for CAD and 
LV  dysfunction.    Myocardial  ischemia  is  induced  by  atherosclerotic  epicardial 
obstruction of coronary artery which is worsened by hypertensive cardiomyopathy as 
this increases the resistance to blood flow across myocardial wall, increased wall 
tension impairs sub endothelial perfusion, and contributes to myocardial stunning. 
Systolic  dysfunction  and  HF  associated  with  hypertensive  cardiomyopathy  may 
develop late as a complication of the hypertensive process. Although resting systolic 
function  remains  normal  in  hypertensive  persons  for  a  considerable  period,  even 
when LVH is present, systolic dysfunction may become more apparent with exercise 
[14]. Thus, although diastolic dysfunction maybe the predominant finding in LVH, 
there is increasing evidence that there are small but important adverse changes in 
systolic function. 
 
Endothelial Dysfunction in Metabolic Syndrome: 
Mechanisms that contribute to alteration in endothelial function 
1.  Free radical accumulation, known to occur to a greater extent in diabetics is 
thought to impair endothelium dependent vasodilatation due to the inactivation 
of nitric oxide. 
2.  Increased  sympathetic  nervous  system  activity  play  a  role  in  endothelial 
dysfunction. Tachycardia is able to increase shear stress in blood vessels. 
3.  Plasma Leptin levels are often increased in over weight patients with type 2 
diabetes  mellitus  and some  experimental  data suggest that leptin  may  induce 
endothelial activation and increase blood pressure probably through sympathetic 
function. 
4.  Increased production and angiotensin II subsequent to high sympathetic activity 
may also reduce available NO leading to endothelial dysfunction. 
 
Endothelial  dysfunction  may  impair  glucose  uptake  and  contributes  to  insulin 
resistance in cardiac myocyte and causes increase in arterial stiffness and HTN. 
 
Hs-CRP,  TNF  and  IL-6  are  increased  in  patients  with  HF  and correlate  with  an 
adverse outcome. High prevalence of abdominal obesity is characteristic of South 
Asians.  In Framingham  study, after adjustments for established risk factors, the risk 
of HF increased by 5% in men and 7% in women with every single increment of  
BMI [15]. SOLVD registry enrolled 6273 patients, CAD was the underlying cause of 
CHF  in  approximately  70%  of  patients,  whereas  hypertensive  heart  disease  was 
considered to be primarily involved in only 7% [16]. In 21 multicentric HF treatment 
trials involving more than 35,000 patients reported in  Nejm since the mid 1980s, 
CAD was  underlying cause of HF in nearly 65% of patients. 
 
LV Remodeling: The component participating in this process are:  (1) The myocytes, 
(2) Extra cellular matrix, and (3) the microcirculation. Post infarction remodeling has 
been  arbitrarily  divided  into  an  early  phase  (within  72  hours)  and  a  late  phase 
(beyond 72 hours).  Left ventricular remodeling results in ventricular thinning and 
dilatation in the infarct zone, myocyte hypertrophy in the non infarct zones, fibrosis, 
and activation of neurohormones. 
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Myocardial-Hibernation/Stunning: Episodes of transient silent myocardial ischemia 
may cause prolonged LVSD that persists after the ischemic insult itself has resolved. 
This  process  is  termed  stunning,  which  is  similar  to  more  severe  and  protracted 
myocardial  stunning  that  results  from  coronary  occlusion  and  reperfusion  [17]. 
Recurrent  episodes  of  myocardial  ischemia  that  produce  repetitive  myocardial 
stunning may contribute to overall LV dysfunction and HF symptoms and contribute 
to sudden death.  
 
Another important mechanism for LVSD with additive effects on LV performance is 
myocardial  hibernation  [18].  Once  considered  a  process  in  which  myocardial 
contraction is down regulated in response to chronic reduction in myocardial blood 
supply [19], the current evidence supports the hypothesis that persistent contractile 
dysfunction  in  patients  with  chronic  CAD  represents  a  process  of  programmed 
disassembly  of  contractile  elements  following  repeated  episodes  of  reversible 
ischemia.  Thus  rather  than  a  “protective”  mechanism,  hibernation  represents  a 
disadvantageous process that, left uncorrected, may lead to apoptosis and myocyte 
loss,  replacement  fibrosis,  graded  and  reciprocal  changes  in  α-  and  β-adrenergic 
receptor density, progressive LVSD, and the risk of ventricular arrhythmias. This 
process may affect a substantial number of HF patients. Among patients with HF, 
CAD,  and  LVSD, approximately  50%  have  evidence  of  viable  but  dysfunctional 
myocardium. Hibernation-myocardium should be suspected in all patients with CAD 
and  chronic  LVSD  of  any  degree. This  may  be  diagnosed  by  advanced imaging 
techniques.  
 
Although hypertension increases the risk of developing heart failure significantly, 
only minimal evidence exists to suggest that hypertension is an independent outcome 
risk predictor once heart failure is present [20]. Certainly, hypertension is related to 
symptomatic deterioration and development of a congestive state. The PRAISE study 
suggested that history of hypertension was actually associated with a better prognosis 
[21]. Diabetes was an independent predictor of morbidity and mortality in patients in 
the  SOLVD  trial,  SOLVD  registry,  and  other  studies  [22].  Clearly  diabetes  is  a 
significant risk factor for the development of heart failure in the first place, and is 
twice as strong risks factor among women than among men [23]. The combination of 
hypertension and diabetes seems particularly devastating with the risk of developing 
heart failure increased by a factor of 5. 
 
Pulmonary hypertension:  Secondary to LVSD or of any etiology, affects survival by 
causing right ventricular dysfunction and precipitating malignant arrhythmias. 
 
Systolic pulmonary artery pressure significance in Heart failure: Previous studies 
have shown SPAP is not just a marker of severe LV dysfunction but could also be 
one  of  the  mechanisms  by  which  HF  progresses.  25%  of  the  HF  patients  had 
significantly elevated SPAP, which was measured with right ventricular tricuspid 
gradient (RVTG).  SPAP >45 mm Hg is associated with worsening course of HF. 
The prognosis of HF with respect to SPAP is strongly dependent to the attributing 
factors that precipitate pulmonary venous hypertension like LV dysfunction, mitral 
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In  patients  who  have  a  PCWP  decreased to less  than  16  mm  Hg  on  vasodilator 
therapy 1 year survival is 82% vs. 38% among those who did not [24].  Report noted 
that in patients with pulmonary vascular resistance greater than 2.5 wood units who 
were receiving nitroprusside, those that decreased their resistance had a 3 months 
mortality  of  about  4%  compared  with  those  without  change  whose  3  months 
mortality  was  almost  40%.  These  observations  have  lead  many  clinicians  to 
aggressively tailor medication treatments in patients in an attempt to decrease PCWP 
& pulmonary artery pressures.  
 
Multivariate analysis has been identified pulmonary capillary wedge pressure at rest 
and  peak  exercise  stroke  work  index,  as  independent  predictors  of  mortality  in 
patients with heart failure [25]. Pulmonary hypertension as a result of LV diastolic 
failure is common but often unrecognized. It can occur with or without LV systolic 
failure. The most common risk factors are hypertensive heart disease; coronary artery 
disease;  and  impaired  LV  compliance  related  to  age,  diabetes,  obesity,  and 
hypoxemia.  Symptoms  of  orthopnea  and  paroxysmal  nocturnal  dyspnea  are 
prominent.  Many  patients  improve  considerably  if  LV  end  diastolic  pressure  is 
lowered, but current treatments are unsatisfactory. 
 
Material and Methods 
This  cross  sectional  study  consists  100  cases  of  HF  with  and  without  metabolic 
syndrome. Patients were randomly selected   irrespective of sex and evaluated. 
 
Follow up of the Cases: Patients meeting to the criteria underwent the following 
evaluations at base line. NYHA class, Six minute walking test, 2-D Echo and QRS 
interval. Base line variables were reevaluated at one, three, and six months after 
randomization. The study has 2 primary end points (NYHA and the distance walked 
in 6 m), and 3 secondary end points (LVEF%, LVEDD (mm),SPAP (mm), QRS 
duration (ms), and a clinical composite response, which assigns the patients into one 
of the three response groups.  
    
Improved 
  as    Worsened 
Unchanged 
 
In addition death percentage was considered in account. 
 
Statistical  analysis:  All  end  points  were  analysed  for  prognostification  of  heart 
failure.  For  categorical,  end  points  differences  in  distribution  of  responses  to 
treatment at six months in the two groups were compared with the T value. Data are 
presented as mean ± SD changes from base line to six months. All p values are two 
sided. 
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Inclusion Criteria 
1)  60 Patients with moderate to severe symptoms of heart failure in middle age (40-
60)  years  with  metabolic  syndrome  based  on  NCEP  definition  with  waist 
circumference in place of BMI associated with an ejection fraction of < 40% and 
QRS duration > 130 ms. 
2)  40 patients of Heart failure in middle age without metabolic syndrome taken with 
an LVEF < 40% and QRS duration > 130 ms. 
 
Exclusion Criteria 
1)  Heart failure with valvular disease 
2)  Patients with  pacemaker 
3)  Patients with Heart Rate > 140 on, SBP less than 80 mm Hg 
4)  Patients with thyroid dysfunction. 
 
 
Evaluation of functional parameters 
￿  LVEF 
￿  LVEDD 
￿  SPAP 
￿  NYHA Functional classification 
￿  Walk Test : 6- Minute walk test 
￿  QRS COMPLEX 
 
Results 
Table-1: Age wise distribution of cases 
Age 
group 
HF with 
Metabolic 
Syndrome 
% 
HF without 
Metabolic 
syndrome 
% 
40-45  5  8.3%  3  7.5% 
46-50  8  13.4%  7  17.5% 
51-55  27  45.0%  10  25.0% 
56-60  20  33.3%  20  50.0% 
Total  60  100.0%  40  100.0% 
 
 
Table-2: Sex wise distribution of cases 
  0  % 
HF without 
Metabolic 
syndrome 
% 
Male  25  41.6%  22  55.00% 
Female  35  58.4%  18  45.00% 
Total  60  100.0%  40  100.0% 
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Effect on primary end points: 
Table-4: Improvement / change in NYHA class - 24 weeks follow up 
  HF with Metabolic 
Syndrome  %  HF without 
Metabolic syndrome  % 
Improvement by 
2 class  20  33.3%  30  75% 
Improvement by 
1 class  9  15.0%  -  - 
No change   13  21.67%  5  12.5% 
Worsened  8  13.3%  1  2.5% 
 
Table-5: Change in the distance walked in 6 minutes 
HF with Metabolic 
Syndrome 
HF with out 
Metabolic Syndrome  Time 
Mean  SD  Mean  SD 
T  P 
On admission   -  -  -  -  -  - 
1 month  262.24  ± 34.10  311.78  ± 5.7  3.3  <0.002 
3 months  211.61  ± 33.22  324.39  ±11.91  3.6  <0.002 
6 Months  285.35  ± 3.30  336.40  ± 16.0  3.3  <0.002 
 
Effect on secondary end points: 
 
Table-6: Changes in the serial monitoring of ejection fraction 
HF with Metabolic 
Syndrome 
HF with out 
Metabolic Syndrome  Time 
Mean  SD  Mean  SD 
T  P 
On admission   29.53  ± 1.86  31.08  ± 2.60  1.1  <0.240 
1 month  30.78  ± 2.00  33.47  ± 1.59  2.579  <0.010 
3 months  31.42  ± 2.49  34.64  ± 1.59  2.670  <0.008 
6 Months  31.63  ± 2.74  35.22  ± 1.71  2.723  <0.006 
 
Table-7: Changes in the QRS duration 
HF with Metabolic 
Syndrome 
HF with out 
Metabolic Syndrome  Time 
Mean  SD  Mean  SD 
T  P 
On admission   146.97  ± 4.66   142.03  ± 4.11  1.947  <0.052 
1 month  145.23  ± 5.06  141.11  ± 2.26  1.821  <0.070 
3 months  144.95  ± 5.18  139.11  ± 2.36  2.513  <0.012 
6 Months  143.92  ± 6.07  138.00  ± 2.03  2.266  <0.024 
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Table-8: Changes in LVEDD 
HF with Metabolic 
Syndrome 
HF with out 
Metabolic Syndrome  Time 
Mean  SD  Mean  SD 
T  P 
On admission  62.43  ± 5.59  51.95  ± 3.9  3.4  <0.002 
1 month  64.32  ± 3.84  53.94  ± 2.87  4.915  <0.002 
3 months  64.47  ± 3.65  54.42  ± 2.79  5.305  <0.002 
6 Months  65.04  ± 3.29  54.61  ± 2.76  5.459  <0.002 
 
Table-9: During 24 weeks follow up No. of patients required repeated admissions or 
use of intravenous medications 
  HF with Metabolic 
Syndrome  Percentage  HF without 
Metabolic syndrome  Percentage 
No. of 
Patients  30  50%  10  25% 
Total  30  50%  10  25 
 
Table-10: Age wise distribution of deaths 
Age group  HF with Metabolic 
Syndrome  Percentage  HF without 
Metabolic syndrome  Percentage 
40-45  -  -  -  - 
46-50  2  3.3%  -  - 
51-55  2  3.3%  1  2.5% 
56-60  6  9.9%  3  7.5% 
Total  10  16.50%  4  10% 
 
Table-11: Sex wise distribution of deaths 
Sex  HF with Metabolic 
Syndrome  Percentage  HF without 
Metabolic syndrome  Percentage 
Male  3  5%  2  5% 
Female  7  11.6%  2  5% 
Total  10  16.50%  4  10% 
 
 
Discussion 
Diabetic men have more than twice the frequency of HF than non-diabetic cohorts, 
diabetic women have a 5 fold increased risk of HF.  The role of metabolic control of 
diabetes in the prevention or reversal of myocardial dysfunction is unclear.  
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HF usually results when HTN coexist with other diseases that affect the myocardium 
(Ex: CAD, DM2). Increasing BMI in HF is associated with a lower mortality, but 
influence is complex and depends on LV systolic function and obesity may indicate 
an  increased  risk.  Many  workers  across  the  globe  are  studying  these  interesting 
combinations. 
 
Variables Relevant to Prognosis of Heart Failure: The clinical variables related to 
adverse  outcome  in  heart  failure  have  emerged  from  the  observations  made  in 
numerous anecdotal reports, case series and clinical trials. Cowborn and Coworkers 
summarized  Peer-reviewed  publications  containing  more  than  200  subjects  with 
chronic  heart  failure  in  which  a  multivariate  analysis  of  prognostic  factors  were 
reported. 
 
When HF is diagnosed, NYHA classification, LVEDD, LVEF% stroke work index, 
peak  oxygen  consumption  on  metabolic  exercise,  treadmill  testing,  pulmonary 
capillary wedge pressure, hepatic dysfunction, hypertension, hypotension, age and 
chest x-ray cardiothoracic ratio, pulmonary atrial pressure as independent markers of 
adverse outcome. Gender is a controversial issue with respect to prognosis. 
 
Age and Sex distribution of cases: HF tends to increase with increasing age. In the 
present study the number of patients over 56-60 years are 40 (40%). Out of the 40 
patients, 20 patients have metabolic syndrome, 20 patients are without metabolic 
syndrome. In metabolic syndrome group highest number of patients were in 51-55 
years  age  group.  This  is  comparable  to  Framingham  study,  which  reported  that 
prevalence of HF is 2% by the age of 40 – 49 years, 5% by the age of   50-59 years, 
10% by the age over 70 years. In metabolic syndrome highest number of cases in the 
age group of   51-55 years because the incidence of M.S in India is highest between 
the  age  group  of  40-50  years  (33.7%).  In  metabolic  syndrome  group  58.4%  are 
females and 41.6% are males.  This can be compared with Framingham study, which 
reported  that  the  relative  risk  for  diabetic  men  and  women  was  3.8  and  5.5 
respectively, when compared with non-diabetic patients.In patients without metabolic 
syndrome group. 45% are females and 55% are males. This can be compared to 
Framingham study, which recently reported that life time risk of HF is 21% in men 
and 20% in females. According to Iribareen and colleagues - CHF onset was directly 
related to HBA1C  levels, with a level greater than 10% more than doubled the rate of 
onset of CHF compared with HBA1C  level of less than 7%.  This is comparable to 
the present study.  In the present study out of 100 patients with HF 60 patients have 
metabolic syndrome and 40 patients are without metabolic syndrome. 
 
Effect on Primary End points 
1. Improvement / Change in the NYHA Class: Gross assessments of the symptomatic 
severity by the NYHA functional classification. 
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In  all  these  prognostic  studies  patients  were 
considered  improved  when  improvement  in 
NYHA functional class was equal or more than 
two. In the present study out of 60 patients with 
metabolic syndrome, after 24 weeks of follow 
up  the  no.  of  patients  with  improvement  in 
NYHA  class  by  2  or  more  are  20  (33.3%), 
where as out of 40 patients without metabolic 
syndrome, the no. of patients with improvement 
in NYHA class by 2 or more was 30 (75%). In 
the  present  study  Out  of  60  patients  with 
metabolic  syndrome  13  (21.6%)  patients 
showing  no  change  in  the  NYHA,  while  in 
patients without metabolic syndrome 12.5% are 
patients showing no change in NYHA. 
 
Based on the previous studies, Gross functional improvement is more in the HF 
patients without metabolic syndrome, than HF patients with metabolic syndrome. 
 
2. Distance Walked in 6 minutes: According to solved registry – A 6 minutes walk 
test is safe and simple clinical tool that strongly and independently predicts mortality 
and morbidity in patients with LV dysfunction. 
 
In  the  Solved  registry,  LVEF  and  distance 
walked  in  6  min  are  equally  strongly  and 
independent  predictors  of  mortality  and 
morbidity.  This  is  comparable  to  the  present 
study.  The distance walked in 6 min after 24 
weeks (in meters) of follow up in patients with 
metabolic syndrome is 285.35 ± 3.30, where as 
in  patients  without  metabolic  syndrome  the 
distance walked in 6 min after 24 weeks of follow up is 336.40 ±  16.0. The no. of 
frequent hospitalizations or use of intravenous medication is highest in the metabolic 
syndrome  patients  than  patients  without  metabolic  syndrome  (50%  Vs.  25%). 
Previous studies have shown high death rate in lowest performance group of patients 
when compared with highest performance group.  This is comparable to the present 
study  in  which  metabolic  syndrome  group  have  lowest  performance  level  than 
patients without metabolic syndrome, the mortality rate is more in the metabolic 
syndrome group (16.6% Vs. 10%). 
 
Effect on the Secondary End Points 
1. Serial Monitoring–Absolute change in the LVEF: According to V-HeFT data. In 
HF  patients  a  single  measurement  of  LVEF  provides  important  prognostic 
information  and  serial  measurements  of  LVEF  provide  additional  important 
prognostic  information.  According  to  SOLVD  registry,  EF  is  a  strong  and 
independent predictor of mortality and HF hospitalization during follow up. 
Previous prognostic studies – used 
NYHA in prognostification of HF 
Name  Year 
Keogh  1990 [26]
 
Bittner  1993 [27] 
Compana  1993 [28] 
Gianuzzi  1996 [29] 
Adams  1996 [30] 
Permonkil  1997 [31] 
Gomes  1997 [32] 
Bart  1997 [33] 
Soifer  1997 [34] 
Previous studies – used 6 min walk 
test in prognostication of HF 
Name  Year 
Cohn  1993 [35] 
Mahon  2002 [36] 
Adams  1997 [37] Al Ameen J Med Sci; Volume 5, No.3, 2012                                                                     Abdullah BB et al 
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The  present  study  comparable  to  SOLVD 
registry, in metabolic syndrome group after 24 
weeks of follow up the EF was 31.63 ± 2.74, 
where  as  in  patients  without  metabolic 
syndrome after 24 weeks of follow up the EF 
was  35.22  ±  1.71.    This  results  in  increased 
mortality  and  frequent  hospitalizations  in 
metabolic syndrome group (16.6% Vs 10% and 
50% Vs. 25%). The present study is comparable 
to V-HeFT data, on serial monitoring of EF the 
improvement in EF is more in patients without 
metabolic syndrome and improvement after 24 
weeks of follow up is more in patients without 
metabolic  syndrome  than  patients  with 
metabolic syndrome (75% Vs. 33.3%). 
 
2. Change in the LVEDD: LVEDD vary widely, well coordinated male athlete have 
an average LVEDD of 56 ± 3 mm. In normal women the average LVEDD is 47 ± 3 
mm. According to Unverferth (1984), patients with HF with a very dilated heart are 
known to have poor prognosis. This is comparable to present study.  In the present 
study both groups have increase in LVEDD.  LVEDD is significantly more in the 
MS group (65.04 ± 3.29 Vs. 54 ± 2.76) and with this the overall prognosis is poor 
(Mortality 16.6% Vs. 10% and Morbidity 50% Vs 25%).  
 
According  to  Lee  TH  (1993), 
Echocardiographic measurements - LVEDD 
> 75 mm or > 40 mm / m
2 is associated with 
sudden death.  In the present study no patient 
have LVEDD > 75 mm.  
 
 
Change in the QRS duration: A study conducted by Heather J. Shenkman showed 
that there was a linear relationship between increased QRS duration and increased 
EF.  This is comparable to present study.  In the M.S. group after 24 weeks follow up 
the QRS duration is 143.92 ±  6.07 and EF is 31.63 ± 2.74 where as patients without 
MS after 24 weeks follow up the QRS duration was 138.0 ± 2.83 and EF was 35.22 ± 
1.71. According to Cleland (1987), Xiao HB (1996), Olshausen (1988), Brembilla 
parrot B (1997), intraventricular conduction delay with LBBB and prolongation of 
QRS interval has been associated with poor outcome in patients with HF and dilated 
cardiomyopathy. 
 
The  present  study  is  comparable  to  above 
observations,  the  QRS  interval  after  24 
weeks  of  follow  up  is  143  ±  6.07  in 
metabolic syndrome group and 138 ± 2.03 in 
the patients without metabolic syndrome.  
 
Previous prognostic studies - used 
EF as prognostic predictor in HF 
Name  Year 
Gradman  1989
 [38] 
Sterenson  1992
 [39] 
Bittner  1993 [27] 
Giannuzzi  1996 [29] 
Adams  1996 [30] 
Gomes  1997 [32] 
Bart  1997 [33] 
Venkateswar  1999
 [40] 
Juliano  2002
 [41] 
Sarnak  2002
 [42] 
Previous prognostic studies-used 
LVEDD as prognostic predictor in HF 
Name  Year 
Demaria  1992 [43] 
Saxon  1993
 [44] 
Previous prognostic studies used QRS 
duration as prognostic predictor in HF 
Name  Year 
Venkateswar  1999 [40] 
Juliano  2002 [41] Al Ameen J Med Sci; Volume 5, No.3, 2012                                                                     Abdullah BB et al 
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The prognosis i.e. mortality and morbidity is highest in the QRS prolonged group i.e. 
metabolic syndrome group (16.6 Vs. 10%, 50% Vs. 25%) 
 
Age and Sex wise distribution of Death: The SOLVD data identified diabetes as a 
strong predictor of mortality in patients with CHF.  The present study is comparable 
to the above data as more deaths are noticed in the metabolic syndrome group.   In  the 
Rancho Bernardo Study, diabetic women had ischemic heart disease mortality rates 
higher to both nondiabetic and diabetic men, while nondiabetic women had a clear 
longevity advantage. In addition, case fatality rates following a myocardial infarction 
are  as  great  or  greater  for  diabetic  women  relative  to  nondiabetic  women  as for 
diabetic men. In the present study, out of 60 patients with metabolic syndrome 7 
females and 3 males died, where as in 40 patients without metabolic syndrome 2 
females and 2 males died. Age is one of the stronger and consistent predictor of 
adverse outcome in chronic heart failure.   
 
In V-Heft trial, in the older cohorts, the risk of death or repeated hospital admission 
for congestive heart failure over a 12 months period of time approached 50%.  This is 
comparable to metabolic syndrome group, as highest deaths are noted in the age 
group 56-60 years. 
 
Observations during 24 weeks follow up 
Electrocardiography: In the present study atrial fibrillation worsened heart failure in 
4 patients with metabolic syndrome and 1 patient without metabolic syndrome. When 
high  frequency  premature  contractions,  couplets,  are  non  sustained  ventricular 
tachycardia is present during ambulatory monitoring, heart failure patients seem to be 
worse.  In  the  present  study  in  patients  with  metabolic  syndrome  4  patients  had 
sudden death. 
 
First and Second degree atrial ventricular block and intraventricular conduction delay 
with left bundle branch block has been associated with poor outcome with heart 
failure and dilated cardiomyopathy. Interestingly, intraventricular conduction delay 
or left bundle branch block is not as powerful a predictor of high mortality when 
compared ischemic heart disease is the etiology. 
 
Conclusion 
In 100 cases of moderate to severe heart failure (60 with metabolic syndrome, 40 
without      metabolic  syndrome)  were  monitored  for  a  period  of  24  weeks.  The 
primary  end  points  were  improvement  in  NYHA  distance  walked  in  6  minutes.  
Secondary end points were LVEF, LVEDD, QRS duration. 
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Effect on End points: 
End Points 
HF with 
Metabolic 
Syndrome 
 
HF with out 
Metabolic 
Syndrome 
%  T  P 
Change in NYHA Class  %    %     
Improved by 2 or 
more class  20  33%  30  75%     
Improved by 1 class  9  15%  -  -     
No change  13  21%  5  12.5%     
Worsened  8  13%  1  2.5%     
Distance walked in 6 minutes  SD    SD     
Mean  285.35  ± 3.30  336  ± 1.60  3.3  <0.002 
Absolute change in LV EF%           
Mean  31.63  ± 2.74  35.22  ± 1.71  2.7  <0.006 
Change in LVEDD (mm)           
Mean  65.04  ± 3.29  54.61  ± 2.7  5.4  <0.002 
Change in QRS interval (ms)         
Mean  143.92  ± 6.07  138.00  ± 2.03  2.26  <0.002 
 
Effect on primary End points: As compared with metabolic syndrome group, patients 
without metabolic syndrome had improvement in the distance walked in 6 minutes, 
and the NYHA functional class (p < 0.002 and 75% improved. 
 
Effect on Secondary End Points: As compared with metabolic syndrome, patients 
without metabolic syndrome had an improvement in two measures LVEF and QRS 
intervals. At the end of 24 weeks follow up, the condition of more patients in group 
without metabolic syndrome was considered to be improved ( 75% Vs 48.3%) and 
fewer were considered worsened (2.5% Vs 13.3 %) 
 
Effects on death and on worsening heart failure: In the intention to treat analysis, 
there were 10 deaths in metabolic syndrome group and 4 deaths in patients without 
metabolic syndrome (16.6% Vs. 10%) – “mortality”. Differences between the groups 
in the frequency of hospitalizations (or) the use of an intravenous medication were 
significant (50% Vs. 25%) – “morbidity”. 
 
Summary 
“Metabolic  Syndrome  is  a  detrimental  prognostic  predictor  of  middle  aged 
individuals with heart failure and retrieves the outcome in reference to age, sex, 
NYHA improvement, distance walked in 6 min, LVEF, LVEDD, SPAP and QRS 
duration. As such innumerable prognostic predictors are pointed till date. Metabolic 
syndrome perse could be an independent prognostic predictor and there yet remains 
paucity  of  its  literature.  Patients  of  metabolic  syndrome  with  HF  once  being 
symptomatic prognosis is relatively poor with mortality rate of 16.6% and morbidity 
of 50%.  Al Ameen J Med Sci; Volume 5, No.3, 2012                                                                     Abdullah BB et al 
© 2012. Al Ameen Charitable Fund Trust, Bangalore  285 
 
Heart failure with metabolic syndrome is associated with considerable morbidity that 
impairs quality of life by interfering with their ability to perform activities of daily 
living.  
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